Ucello Therapeutics
Chengdu
About Ucello Therapeutics
Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $60.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2023)
- Website: ucello.cn
- Phone: +86 028 84729134
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/ucello-therapeutics-29006 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.